Business Wire

NY-DAVIS-POLK

17.1.2023 16:34:38 CET | Business Wire | Press release

Share
Davis Polk to Launch EU Antitrust Practice in Brussels

Davis Polk today announced that the firm is launching a European antitrust practice in Brussels. The practice will be led by Jürgen Schindler and Frances Dethmers.

“The European Commission is a critical antitrust authority. We are excited to be able to offer our clients sophisticated antitrust capabilities with respect to matters under EU law,” said Neil Barr, Davis Polk’s Managing Partner. “We are thrilled to welcome Jürgen and Frances to Davis Polk.”

The firm’s office in Brussels will open in 2023.

Mr. Schindler and Ms. Dethmers join the firm from Allen & Overy, where both served as partners and Mr. Schindler as co-head of the global competition and antitrust group. Mr. Schindler has extensive experience advising clients on complex international, EU and German merger control, cartel and abuse of dominance cases. His practice encompasses a broad range of sectors, including energy, finance, technology, transport (shipping and airlines), raw materials, chemicals, pharmaceuticals, and consumer and industrial products. In addition, Mr. Schindler litigates before the European courts in Luxembourg.

Mr. Schindler’s practice has extensive geographic coverage; he has advised clients in Europe, the United States, Latin America, Asia and the Middle East. He is admitted to practice in Germany, Belgium and New York. He will join Davis Polk as a partner.

He is a Non-Governmental Adviser to the European Commission and to the German Competition Authority at the International Competition Network (ICN), which includes around 140 competition authorities worldwide, and he regularly contributes to the ICN’s cartel and merger working groups. In addition, he is a long-time editorial board member of the ABA’s Antitrust Magazine Online.

Ms. Dethmers’ practice focuses on international, EU and Dutch competition law. She is an economist and a qualified lawyer. She has extensive experience advising clients from a wide range of industries (in particular, pharmaceuticals, health and life sciences, consumer and industrial products, chemicals and packaging) on highly complex merger control procedures, as well as on cartel investigations, abuse of dominance investigations, intellectual property issues and licensing and distribution agreements. Prior to working in private practice, she worked at the Dutch Competition Authority and the European Commission. Her background as an economist gives her unique insight into the economic concepts and analytical tools at the heart of competition law. She is admitted to practice in the Netherlands. She will join Davis Polk as Special Adviser – EU Antitrust.

“Jürgen and Frances are exceptional lawyers with an outstanding reputation in Brussels, and we are thrilled to have them on board to help us launch our EU antitrust practice,” said Art Burke, head of Davis Polk’s Antitrust & Competition practice. “Their significant experience across merger control matters, cartels and antitrust litigation will benefit our clients greatly and will further solidify our position as a leading global antitrust firm.”

Davis Polk is recognized as a preeminent firm in antitrust and competition law, including with top-tier rankings from publications such as Global Competition Review, Benchmark Litigation and Chambers USA. Clients rely on Davis Polk’s deep experience across the full spectrum of antitrust and competition matters. The firm steers clients through sensitive antitrust investigations and high-stakes litigation, including class actions and government enforcement actions. Davis Polk also serves in a lead role for large defense groups, including in cases alleging cartel behavior in numerous industries and financial markets. Having addressed and resolved antitrust issues presented by thousands of transactions across all economic sectors, the firm is widely recognized in particular for its work on cross-border combinations and routinely acts as coordinating counsel for international merger control review for complex transactions.

Mr. Schindler said, “Frances and I are very excited to be joining Davis Polk, a firm we have long held in high esteem. We have been struck by the strong culture that permeates throughout the firm, and we very much look forward to working with this fantastic team and helping the firm to execute on this strategic expansion of its global antitrust capabilities. We are very grateful for our time as partners at Allen & Overy.”

Ranked as a leading EU competition lawyer by Chambers Europe, Mr. Schindler in 1999 graduated from the University of Hamburg and earned an LLM in European Law from the College of Europe in Bruges. In 2007, he earned an LLM from Georgetown University Law Center focusing on U.S. antitrust law and economics. Ms. Dethmers earned a master’s degree in economics in 1998 and a master’s degree in law in 2001, both from the University of Amsterdam.

About Davis Polk.

Davis Polk & Wardwell LLP (including its associated entities) is an elite global law firm with world-class practices across the board. Clients know they can rely on us for their most challenging legal and business matters. From offices in the world’s key financial centers and political capitals, our more than 1,000 lawyers collaborate seamlessly to deliver exceptional service, sophisticated advice and creative, practical solutions. Visit davispolk.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005803/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye